The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
OBJECTIVE
To assess the thrombotic risk associated with oral contraceptive use with a focus on dose of oestrogen and type of progestogen of oral contraceptives available in the Netherlands.


METHODS
Population based case-control study.


METHODS
Six participating anticoagulation clinics in the Netherlands (Amersfoort, Amsterdam, The Hague, Leiden, Rotterdam, and Utrecht).


METHODS
Premenopausal women <50 years old who were not pregnant, not within four weeks postpartum, and not using a hormone excreting intrauterine device or depot contraceptive. Analysis included 1524 patients and 1760 controls.


METHODS
First objectively diagnosed episodes of deep venous thrombosis of the leg or pulmonary embolism. Odds ratios calculated by cross-tabulation with a 95% confidence interval according to Woolf's method; adjusted odds ratios estimated by unconditional logistic regression, standard errors derived from the model.


RESULTS
Currently available oral contraceptives increased the risk of venous thrombosis fivefold compared with non-use (odds ratio 5.0, 95% CI 4.2 to 5.8). The risk clearly differed by type of progestogen and dose of oestrogen. The use of oral contraceptives containing levonorgestrel was associated with an almost fourfold increased risk of venous thrombosis (odds ratio 3.6, 2.9 to 4.6) relative to non-users, whereas the risk of venous thrombosis compared with non-use was increased 5.6-fold for gestodene (5.6, 3.7 to 8.4), 7.3-fold for desogestrel (7.3, 5.3 to 10.0), 6.8-fold for cyproterone acetate (6.8, 4.7 to 10.0), and 6.3-fold for drospirenone (6.3, 2.9 to 13.7). The risk of venous thrombosis was positively associated with oestrogen dose. We confirmed a high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives.


CONCLUSIONS
Currently available oral contraceptives still have a major impact on thrombosis occurrence and many women do not use the safest brands with regard to risk of venous thrombosis.
van Hylckama Vlieg
A
A
Department of Clinical Epidemiology, Leiden University Medical Center, C7-P, PO Box 9600, NL-2300 RC Leiden, Netherlands.
Helmerhorst
F M
FM
Vandenbroucke
J P
JP
Doggen
C J M
CJ
Rosendaal
F R
FR
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects*; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000453:epidemiology; D055815:Young Adult
D003278:Contraceptives, Oral, Hormonal; D003280:Contraceptives, Oral, Synthetic; D004967:Estrogens; D011372:Progestins
World Health Organ Tech Rep Ser. 1998;877:i-vii, 1-89
9615606
Arch Intern Med. 1999 Jan 11;159(1):65-70
9892332
Cutis. 2002 Apr;69(4 Suppl):2-15
12096825
Acta Obstet Gynecol Scand Suppl. 1979;88:33-42
160741
Ann N Y Acad Sci. 1995 Jun 12;761:311-35
7625729
Lancet. 1995 Dec 16;346(8990):1575-82
7500748
Lancet. 2000 Jun 17;355(9221):2133-4
10902629
Contraception. 1998 May;57(5):291-301
9673836
J Thromb Haemost. 2005 Nov;3(11):2471-8
16241945
Thromb Haemost. 2000 Jul;84(1):15-21
10928463
Lancet. 1995 Dec 16;346(8990):1593-6
7500751
Hum Reprod Update. 1999 Nov-Dec;5(6):721-35
10652981
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006586
18254106
Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):427-36
15269926
BMJ. 2001 Jul 21;323(7305):131-4
11463678
Lancet. 1995 Dec 16;346(8990):1589-93
7500750
Am J Epidemiol. 1991 Jan;133(1):32-7
1983896
J Thromb Haemost. 2007 Apr;5(4):692-9
17367492
BMJ. 2002 Apr 13;324(7342):869
11950727
BMJ. 2003 Feb 1;326(7383):257
12560278
Lancet. 1997 Jan 11;349(9045):83-8
8996419
Contraception. 1998 Mar;57(3):169-81
9617533
Contraception. 2007 May;75(5):344-54
17434015
Contraception. 1993 Dec;48(6):557-75
8131397
Contraception. 2002 Mar;65(3):187-96
11929640
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004425
17253506
Int J Epidemiol. 1992 Feb;21(1):48-52
1544757
J Clin Endocrinol Metab. 1995 Jun;80(6):1816-21
7775629
Hum Reprod. 2005 Feb;20(2):563-8
15539435
Lancet. 1994 Nov 26;344(8935):1453-7
7968118
Obstet Gynecol. 2007 Sep;110(3):587-93
17766604
Thromb Haemost. 2002 Feb;87(2):199-205
11859850
Lancet. 2001 Oct 27;358(9291):1427-9
11705493
Br Med J (Clin Res Ed). 1986 Feb 22;292(6519):526
3081157
Lancet. 1995 Dec 16;346(8990):1582-8
7500749
Br J Haematol. 2003 Aug;122(3):465-70
12877675
J Thromb Haemost. 2004 Nov;2(11):2060-2
15550051
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003987
16437470
Thromb Haemost. 2000 Jul;84(1):4-8
10928461
Am J Obstet Gynecol. 1997 Oct;177(4):887-91
9369840